365betapp苹果版下载【首頁】

0431-81311122

行业动态

报告:未来6年亚太地区卵巢癌(OC)治疗市场将保持稳步增长

2015-04-09

来源:生物谷 2015-04-08

2015年4月1日讯 /生物谷BIOON/ --全球知名市场调研公司GBI Research发布研究报告指出,未来6年(2014-2020),亚太地区(APAC)卵巢癌(OC)治疗市场将以5.1%的年度复合增长率(CAGR)稳步增长,到2020年达到4.176亿美元。该市场在2013年市值2.943亿美元。

日本在亚太地区卵巢癌治疗市场中占据最大的市场份额,2013年为62%;其次是中国,市场份额为16.5%;其余为澳大利亚、印度及其他国家。总体上,在预测期间内,亚太地区卵巢癌治疗市场将保持稳步增长,这主要是由于该地区患病人群的增长,尤其是印度和中国。

报告指出,卵巢癌治疗中2个关键未获满足的临床需求也将激励亚太地区市场在预测期间内的稳步增长:其一是铂耐药卵巢癌患者对有效治疗药物的临床需求;其二是经一线和二线治疗后,患者需要一种有效的维持疗法,来延长疾病无进展生存期(PFS),这一需求集中体现在铂敏感卵巢癌群体。之前在临床获得成功的新药,将进一步激励卵巢癌领域的药物研发。

报告还指出,目前卵巢癌药物管线从早期到晚期阶段均有稳定数量的候选药物,在整个预测期间内预计将持续有新药上市。然而,尽管晚期管线已十分拥挤,但还没有药物在总生存期(OS)方面表现出显著改善,大多数后期管线药物所能提供的临床利益十分微弱,与当前标准护理相比,仅仅是无进展生存期(PFS)方面轻度至中度的改善。最有前途的实验性药物olaparib(阿斯利康研发,已在欧美获批)和trebananib(安进研发)预计将于预测期内在亚太地区上市,然而这些药物预计不会达到很高的市场渗透,主要是由于有限的疗效和预期的高昂价格。

另一方面,仿制药在亚太市场中的充斥将限制这些预期新药在4个主要亚太地区国家中的处方容量。其结果是,整个亚太地区卵巢癌治疗市场在2020年以前不会出现急剧的变化,而只会平稳的增长。值得一提的是,这一增长预计不是由新药上市刺激,而是由通货膨胀(inflation)以及卵巢癌发病率的升高驱动。

然而,尽管当前后期管线药物的临床表现不尽如意,但有迹象表明制药行业对卵巢癌市场仍继续保持浓厚兴趣,具体表现在早期管线中有大量的候选药物,尤其是临床前阶段。同时,有广泛的新分子靶标分布在这些候选药物中,包括生长因子、丝氨酸/苏氨酸蛋白激酶、肿瘤相关抗原等。这表明业界对于将更多靶向疗法引入卵巢癌治疗有持续的兴趣,相比肿瘤学其他领域,卵巢癌治疗领域靶向疗法的开发明显滞后。

(力太生物.com)


英文原文:Ovarian Cancer Treatment Market in Asia-Pacific to Undergo Modest Growth by 2020, says GBI Research

The Asia-Pacific (APAC) therapeutics market for Ovarian Cancer (OC) will undergo a modest rise in value, from $294.3 million in 2013 to $417.6 million by 2020, at a Compound Annual Growth Rate (CAGR) of 5.1%, says business intelligence provider GBI Research.

The company’s latest report* states that Japan held the largest share of the regional OC therapeutics space in 2013, with 62%, followed by China with 16.5%. The other markets making up the APAC region are Australia and India.

The modest growth in APAC’s overall market will be driven primarily by an increase in the region’s prevalent population, especially in India and China, which will rise from 160,099 in 2013 to 187,103 by 2020, at a CAGR of 2.3%.

Sravanthi Addapally, Associate Analyst for GBI Research, says: “Two key unmet needs in OC therapeutics will also encourage APAC market growth over the forecast period. One is an effective drug for patients with platinum-resistant disease and the other is a maintenance therapy to extend disease-free survival after initial and second-line treatment, predominately in platinum-sensitive disease.

“The potential revenues that clinically successful products could achieve will encourage further OC drug development by 2020.”

Addapally adds that the current OC treatment pipeline has a steady number of candidates in both the late and early developmental stages, with indications that new approvals will be sustained up to the end of the forecast period and beyond.

However, the analyst continues: “Although the late-stage pipeline is crowded in terms of molecule numbers, no candidates have shown significant improvement in overall survival. Most of the late-stage products provide minimal clinical benefit to patients, with the best responses being mild-to-moderate improvements in progression-free survival in comparison with the current standard of care.

“While these more promising products are anticipated to gain approval by 2020, their expected high cost and limited clinical benefits, combined with the dominance of generic drugs, will limit their prescription volumes in the four APAC countries. As a result, the overall region will not witness a paradigm shift in its OC treatment markets before 2020,” Addapally concludes.


地址:吉林省长春市高新技术产业开发区锦湖大路1357(E)宝孚大厦4006室 电话:0431-81311122
版权所有:长春力太生物科技有限公司 吉ICP备14006071号-1

建站技术支持长春庞智科技